DK1947175T3 - Sekvens af nukleotider og peptider GSE 24,2 af dyskerin, der kan fremkalde telomeraseaktivitet, fremgangsmåde til fremstilling deraf, terapeutiske sammensætninger og anvendelser deraf - Google Patents

Sekvens af nukleotider og peptider GSE 24,2 af dyskerin, der kan fremkalde telomeraseaktivitet, fremgangsmåde til fremstilling deraf, terapeutiske sammensætninger og anvendelser deraf

Info

Publication number
DK1947175T3
DK1947175T3 DK06849419.4T DK06849419T DK1947175T3 DK 1947175 T3 DK1947175 T3 DK 1947175T3 DK 06849419 T DK06849419 T DK 06849419T DK 1947175 T3 DK1947175 T3 DK 1947175T3
Authority
DK
Denmark
Prior art keywords
sequence
dyskerin
gse
telomerase activity
nucleotides
Prior art date
Application number
DK06849419.4T
Other languages
Danish (da)
English (en)
Inventor
Abellon Rosario Perona
Pinilla Rosario Machado
Garzon Leandro Sastre
Perez Isabel Sanchez
Ibanez Jose Ramon Murguia
Original Assignee
Consejo Superior Investigacion
Univ Madrid Autonoma
Univ Valencia Politecnica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior Investigacion, Univ Madrid Autonoma, Univ Valencia Politecnica filed Critical Consejo Superior Investigacion
Application granted granted Critical
Publication of DK1947175T3 publication Critical patent/DK1947175T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
DK06849419.4T 2005-10-14 2006-10-11 Sekvens af nukleotider og peptider GSE 24,2 af dyskerin, der kan fremkalde telomeraseaktivitet, fremgangsmåde til fremstilling deraf, terapeutiske sammensætninger og anvendelser deraf DK1947175T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200502511A ES2325431B1 (es) 2005-10-14 2005-10-14 Secuencia de nucleotidos y peptidos gse 24.2 de la disquerina inductores de la actividad telomerasa, procedimiento de obtencion, composiciones terapeuticas y sus aplicaciones.
PCT/ES2006/070152 WO2007090911A1 (es) 2005-10-14 2006-10-11 Secuencia de nucleótidos y péptidos gse 24.2 de la disquerina inductores de la actividad telomerasa, procedimiento de obtención, composiciones terapéuticas y sus aplicaciones

Publications (1)

Publication Number Publication Date
DK1947175T3 true DK1947175T3 (da) 2010-09-27

Family

ID=38344881

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06849419.4T DK1947175T3 (da) 2005-10-14 2006-10-11 Sekvens af nukleotider og peptider GSE 24,2 af dyskerin, der kan fremkalde telomeraseaktivitet, fremgangsmåde til fremstilling deraf, terapeutiske sammensætninger og anvendelser deraf

Country Status (10)

Country Link
US (2) US9074194B2 (OSRAM)
EP (1) EP1947175B1 (OSRAM)
JP (1) JP5560398B2 (OSRAM)
AT (1) ATE469212T1 (OSRAM)
CA (1) CA2625981A1 (OSRAM)
DE (1) DE602006014574D1 (OSRAM)
DK (1) DK1947175T3 (OSRAM)
ES (2) ES2325431B1 (OSRAM)
PT (1) PT1947175E (OSRAM)
WO (1) WO2007090911A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2334736B1 (es) * 2007-11-23 2011-02-02 Consejo Superior De Investigaciones Cientificas (Titular Al 90%) Uso de agentes inductores gse24.2 para la elaboracion de composiciones farmaceuticas para el tratamiento de enfermedades que cursan con senescencia celular.
WO2014122346A1 (es) * 2013-02-05 2014-08-14 Consejo Superior De Investigaciones Cientificas (Csic) Bionanopartículas biodegradables para liberación del péptido gse24-2, procedimiento de obtención y utilización
PT3061815T (pt) * 2013-10-25 2020-05-18 Univ Madrid Autonoma Péptidos derivados de gse 24.2 para o tratamento de doenças causadas pelo stresse oxidativo e danos no adn
CN114364392B (zh) * 2019-05-02 2025-12-16 德克萨斯大学系统董事会 涉及tert激活治疗剂的方法和组合物
EP4681700A1 (en) 2023-03-17 2026-01-21 Consejo Superior De Investigaciones Científicas - CSIC Gse24.2-derived peptide and uses thereof
ES2989543A1 (es) * 2023-05-22 2024-11-26 Alodia Farm S L U Peptidos para su uso en la prevencion y/o tratamiento de radiodermitis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
DE19817118C1 (de) * 1998-04-17 1999-10-28 Deutsches Krebsforsch Dyskerin und dafür codierende DNA-Moleküle, diese enthaltende Vektoren, Antikörper gegen Dyskerin und die Verwendung dieser Gegenstände

Also Published As

Publication number Publication date
CA2625981A1 (en) 2007-08-16
ES2325431A1 (es) 2009-09-03
EP1947175A1 (en) 2008-07-23
US9587002B2 (en) 2017-03-07
ES2325431B1 (es) 2010-06-28
JP5560398B2 (ja) 2014-07-23
WO2007090911A1 (es) 2007-08-16
ES2360238T3 (es) 2011-06-02
US20090202503A1 (en) 2009-08-13
ATE469212T1 (de) 2010-06-15
US20150337022A1 (en) 2015-11-26
DE602006014574D1 (de) 2010-07-08
US9074194B2 (en) 2015-07-07
JP2009511036A (ja) 2009-03-19
EP1947175B1 (en) 2010-05-26
PT1947175E (pt) 2010-09-02

Similar Documents

Publication Publication Date Title
EP1548032A4 (en) KDR-PEPTIDES AND VACCINES CONTAINING THEM
CY1116285T1 (el) Ανασυνδυασμενες ν-γλυκοζυλιωμενες πρωτεϊνες απο προκαρυωτικα κυτταρα
MY140710A (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
SA522433360B1 (ar) L-أَسْباراجيناز مُعدل
MXPA03000626A (es) Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
WO2002008251A3 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
ATE417595T1 (de) Keratin-bindende polypeptide
WO2002008256A3 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
HRP20171694T1 (hr) Novi pripravci i postupci
JP2006506942A5 (OSRAM)
DE602005020165D1 (de) Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
WO2007076162A3 (en) Antimicrobial cathelicidin peptides
IL206157A (en) Pancreatic elastase protein of type 1, a nucleic acid molecule encoded by a protein
WO2008040190A8 (fr) Petits peptides pour anti-angiogenèse et utilisation de ceux-ci
JP2014529399A5 (OSRAM)
NZ596043A (en) Allergy inhibitor compositions and kits and methods of using the same
WO2010103515A3 (en) Compositions and methods for prevention and treatment of neurodegenerative diseases
WO2010011994A3 (en) Polypeptides and uses thereof
ATE469212T1 (de) Sequenz von nukleotiden und peptiden gse 24.2 aus dyskerin zur herbeiführung von telomerase- aktivität, herstellungsverfahren dafür sowie therapeutische zusammensetzungen und anwendungen davon
MX2011004176A (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo.
DK2289533T3 (da) Epitoppeptider afledt af karendothelvækstfaktorreceptor-1 samt vacciner indeholdende disse peptider
WO2009067225A3 (en) Boceprevir derivatives for the treatment of hcv infections
RU2006119452A (ru) Рекомбинантный белок, обладающий противораковым действием, кодирующий его ген и его применение